Dr. Scott Gottlieb was in an awkward position.

He’s been head of the Food and Drug Administration for just two weeks, and his boss, President Trump, is pushing a federal budget that would undo years of congressional work and risk bringing the agency to a grinding halt.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Speaking of 25 years, 2107 celebrates the launch of Ambien on the market. The review time was 47 months, which was the norm back then. Except for life threatening illness, perhaps we should go back to the pre PDUFA review times, which would also improve safety and fit within Trump’s budget framework. Problem is the incentive compensation structure in Pharmaland is geared to short term performance, and would have be revised, ultimately meaning fewer dollars to renew that membership at the local yacht club and the trophy spouse only gets to drive an A6 instead of an A8.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy